CharlesKing
2021-12-17
Like and comment plz๐๐๐
Adagio Therapeutics Continues Its Wild Ride โ How Two Tests Led To A Triple-Digit Gain
ๅ ่ดฃๅฃฐๆ๏ผไธ่ฟฐๅ ๅฎนไป ไปฃ่กจๅๅธไบบไธชไบบ่ง็น๏ผไธๆๆๆฌๅนณๅฐ็ไปปไฝๆ่ตๅปบ่ฎฎใ
ๅไบซ่ณ
ๅพฎไฟก
ๅคๅถ้พๆฅ
็ฒพๅฝฉ่ฏ่ฎบ
ๆไปฌ้่ฆไฝ ็็็ฅ็ผ่งๆฅๅกซ่กฅ่ฟ็็ฉบ็ฝ
ๆๅผAPP๏ผๅ่กจ็ๆณ
APPๅ ๆๅผ
ๅ่กจ็ๆณ
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690481576,"tweetId":"690481576","gmtCreate":1639701531165,"gmtModify":1639701531765,"author":{"id":3579391265651951,"idStr":"3579391265651951","authorId":3579391265651951,"authorIdStr":"3579391265651951","name":"CharlesKing","avatar":"https://static.tigerbbs.com/d8fbdcf3295ba7f84c1f2205610ea968","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":59,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment plz๐๐๐</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment plz๐๐๐</p></body></html>","text":"Like and comment plz๐๐๐","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690481576","repostId":2192194909,"repostType":4,"repost":{"id":"2192194909","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639701314,"share":"https://www.laohu8.com/m/news/2192194909?lang=&edition=full","pubTime":"2021-12-17 08:35","market":"us","language":"en","title":"Adagio Therapeutics Continues Its Wild Ride โ How Two Tests Led To A Triple-Digit Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2192194909","media":"Investors","summary":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant โ and ADGI stock soared on Thursday.","content":"<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant โ and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Therapeutics Continues Its Wild Ride โ How Two Tests Led To A Triple-Digit Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Therapeutics Continues Its Wild Ride โ How Two Tests Led To A Triple-Digit Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-12-17 08:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>New analyses suggest <b><a href=\"https://laohu8.com/S/ADGI\">Adagio Therapeutics</a></b>' Covid antibody could still tackle the omicron variant โ and ADGI stock soared on Thursday.</p>\n<p>Two studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.</p>\n<p>The news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with <b>Vir Biotechnology</b> and <b>GlaxoSmithKline</b>. Also this week, the duo said their antibody could effectively target omicron.</p>\n<p>\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.</p>\n<h2>ADGI Stock Continues Its Wild Ride</h2>\n<p>Antibody drugs have taken a wild ride on the omicron train.</p>\n<p>Vaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.</p>\n<p>But omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.</p>\n<p>\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.</p>\n<p>The news on Thursday resulted in another flip for ADGI stock, however.</p>\n<p>The laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.</p>\n<h2>Other Antibodies Target Omicron</h2>\n<p>Similarly, on Thursday, <b>AstraZeneca</b> said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.</p>\n<p>AstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.</p>\n<p>Meanwhile, <b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.</p>\n<p>It's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4539":"ๆฌกๆฐ่ก","BK4139":"็็ฉ็งๆ"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192194909","content_text":"New analyses suggest Adagio Therapeutics' Covid antibody could still tackle the omicron variant โ and ADGI stock soared on Thursday.\nTwo studies from renowned laboratories in the U.S. and France suggest Adagio's experimental antibody-based drug, ADG20, fights omicron-induced Covid, Jefferies analyst Michael Yee wrote in a report to clients. In response, ADGI stock rocketed 106% near 13.10.\nThe news is a 180-degree turn from earlier this week when shares plummeted after Adagio said its antibody experienced a huge drop in effectiveness against omicron. Now, Yee says, it appears the Adagio drug is lining up with Vir Biotechnology and GlaxoSmithKline. Also this week, the duo said their antibody could effectively target omicron.\n\"So, maybe Adagio (drug ADG20) is not as bad as previously thought and is in the ballpark of GlaxoSmithKline/Vir which means it has utility and (effectiveness) and has a real role,\" Yee said.\nADGI Stock Continues Its Wild Ride\nAntibody drugs have taken a wild ride on the omicron train.\nVaccines prompt the body to generate virus-blocking antibodies. Antibody-based treatments, on the other hand, simply infuse or inject a person with the virus blockers.\nBut omicron contains numerous mutations to its spike protein, so antibodies find it harder to recognize. Adagio previously said none of omicron's mutations would hurt the effectiveness of its drug. But, on Tuesday, ADGI stock crashed after the company said that theory didn't pan out in further testing.\n\"We said this was a significant surprise because all data suggested their drug should be potent against omicron and even Adagio management said all along (that) all their prior work suggests the conserved binding region and other factors should lead it to be a great antibody against omicron and future variants,\" Yee said.\nThe news on Thursday resulted in another flip for ADGI stock, however.\nThe laboratories found omicron leads to a 20-40 times reduction in the effectiveness of ADG20 against omicron. That's better than the 300-fold drop Adagio estimated on Tuesday, Yee said. He has a 46 price target on ADGI stock.\nOther Antibodies Target Omicron\nSimilarly, on Thursday, AstraZeneca said its antibody is less effective against omicron than it is against the original strain. But that drug, dubbed Evusheld, can still target omicron, AstraZeneca said.\nAstraZeneca stock rose 1.87% near 56.70 in midday trading on the stock market today. Vir stock continued a six-day running spree, jumping 8.5% near 56. On Wednesday, Vir stock broke out of a cup-with-handle base with a buy point at 52.95, according to MarketSmith.com.\nMeanwhile, Regeneron Pharmaceuticals stock crept down 3.5% near 635. The company said its currently authorized antibody regimen loses effectiveness against omicron. But, Regeneron said, its next-generation antibodies can target omicron and delta. Those antibodies don't have authorization, however.\nIt's important to note that ADGI stock is lowly rated across IBD Digital measures. Shares have a rock-bottom Relative Strength Rating of 1, putting its 12-month performance in the bottom 1% of all stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1017,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690481576"}
็ฒพๅฝฉ่ฏ่ฎบ